Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilisation and recruitment in apolipoprotein E knockout mice

Nonindustry-Sponsored Preclinical Studies on Statins Yield Greater Efficacy Estimates Than Industry-Sponsored Studies: A Meta-Analysis

“…Other statins studied included fluvastatin (12%, 6/49), lovastatin or rosuvastatin (8%, 4/49), and cerivastatin or pitavastatin (6%, 3/49). Of the 63 studies, five studies [22]–[26] evaluated multiple statins, of which four were included in the meta-analysis [22]–[24],[26].…”

Update on statin-mediated anti-inflammatory activities in atherosclerosis

“…Atherogenesis is also regulated by PI3K/Akt pathway. Statins induce their activation on vascular and immune cells, thus, reducing atherosclerotic lesions in ApoE knockout mice [208] and endothelial dysfunction in type 2 diabetic mice [209]. Controversial results on statin-mediated MAPK phosphorylation have been showed.…”

Pre-Procedural Atorvastatin Mobilizes Endothelial Progenitor Cells: Clues to the Salutary Effects of Statins on Healing of Stented Human Arteries

“…Statins induce a robust mobilization of murine CD117+/Sca-1+ progenitor cells and EPCs via the PI3K/Akt pathways and enhance endothelialization of injured vessels thereby leading to attenuation of neointimal formation [7]–[10]. Moreover, recent clinical trials show an LDL-independent superiority of intensive compared to moderate statin therapy in reducing target vessel revascularization in patients who undergo PCI for acute coronary syndromes [11].…”